A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).
TPS5092 Background: Accurate localization of sites of disease is essential for delivering
optimal care to patients with prostate cancer. This is especially true for patients who may …
optimal care to patients with prostate cancer. This is especially true for patients who may …
Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known …
5012 Background: Accurate detection of prostate cancer is imperative to patient
management, yet standard imaging methods perform poorly in accurately detecting mPC …
management, yet standard imaging methods perform poorly in accurately detecting mPC …
[HTML][HTML] [18F] DCFPyL PET/CT for imaging of prostate cancer
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET)
has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent …
has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent …
Results from the OSPREY trial: A prOspective phase 2/3 multi-center study of 18F-DCFPyL PET/CT imaging in patients with pRostate cancer-examination of diagnostic …
586 Objectives: Prostate-specific membrane antigen (PSMA) is a transmembrane protein
that is overexpressed by prostate cancer (PCa) cells. PSMA-based imaging is considered …
that is overexpressed by prostate cancer (PCa) cells. PSMA-based imaging is considered …
A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer …
TPS5093 Background: Early and accurate detection of recurrent or metastatic prostate
cancer remains an unmet diagnostic need for patient management. While agents for …
cancer remains an unmet diagnostic need for patient management. While agents for …
18F-DCFPyL PET/CT in Men with Prostate Cancer
KA Zukotynski, PH Kuo - Radiology, 2022 - pubs.rsna.org
Phillip Kuo, MD, PhD, trained in internal medicine, nuclear medicine, and radiology and is
professor of medical imaging, medicine, and biomedical engineering at University of …
professor of medical imaging, medicine, and biomedical engineering at University of …
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary …
M Wondergem, FM Van Der Zant, WAM Broos… - European Journal of …, 2021 - Springer
Purpose Prostate-specific membrane antigen (PSMA) PET/CT shows better diagnostic
performance for detection of lymph node and bone metastases as compared to conventional …
performance for detection of lymph node and bone metastases as compared to conventional …
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and …
9 Background: Current imaging modalities are suboptimal for the initial staging of men at risk
of harboring occult metastatic prostate cancer (PCa). PSMA-based imaging is considered …
of harboring occult metastatic prostate cancer (PCa). PSMA-based imaging is considered …
Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer
A Basso Dias, A Finelli, G Bauman, P Veit-Haibach… - Radiology, 2022 - pubs.rsna.org
Background Data regarding 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine 3-carbonyl)-amino]-
pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer …
pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer …